Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 56 of the 58 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate glucose-dependent insulinotropic polypeptide (GIP) secretion in patients with type 2 diabetes and nondiabetic control subjects during oral glucose or meal tests. RESEARCH DESIGN AND METHODS: Eligible trials were identified by The Cochrane Library, MEDLINE, Embase, and Web of Science. Data were retrieved and random-effects models for the primary meta-analysis, random-effects meta-regression, and subgroup and regression analyses were applied. RESULTS: Random-effects meta-analysis of GIP responses in 23 trials during 28 different stimulation tests showed that patients with type 2 diabetes (n = 363) exhibited no significant differences (P = not significant) in peak plasma GIP, total area under the curve (tAUC), time-corrected tAUC (tAUC × min−1), and time-corrected incremental area under the curve (iAUC × min−1) in comparison with nondiabetic control subjects (n = 325) but had lower GIP responses as evaluated from iAUC (weighted mean difference, −648 pmol/L × min; 95% CI, −1,276 to −21). Fixed-effects models meta-analyses confirmed most of the results of the primary meta-analysis but showed iAUC × min−1 to be reduced and showed tAUC and tAUC × min−1 to be higher in diabetic patients. Random-effects meta-regression of the primary meta-analysis showed that age (peak GIP, tAUC, iAUC, and iAUC × min−1), BMI (tAUC, iAUC, and iAUC × min−1), and HbA1c (iAUC and iAUC × min−1) predicted some of the GIP outcomes. Post hoc subgroup analysis showed a negative influence of age and of HbA1c on GIP responses and showed a positive influence of BMI on GIP responses. CONCLUSIONS: Our results suggest that patients with type 2 diabetes are characterized by preserved GIP secretion in response to oral glucose and meal tests. They also suggest that high BMI is associated with increased GIP responses but increasing age and HbA1c are associated with reduced GIP secretion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Current research indicates that although GLP-1 secretion is preserved in individuals with T2DM, there is an impairment of GLP-1 function. This includes reduced ability to secrete insulin, heightened insulin resistance, and elevated blood sugar levels, potentially resulting in diminished expression of GLP-1 receptors and developing GLP-1 resistance.10”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Self-citationNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Self-citationLaferrère, B., Heshka, S., Wang, K., Khan, Y., McGinty, J., Teixeira, J., Hart, A. B., & Olivan, B. (2007) · Diabetes Care · doi:10.2337/dc06-1549 · Cited by 532
Self-citationVilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528
Self-citationNauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506
Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · cited 1×
“Many factors previously have been positively associated with GIP responses, including BMI (34,45), female sex (28), and metformin treatment (22).”
BackgroundSelf-citationDeacon, C. F., Nauck, M. A., Meier, J., Hücking, K., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6855 · Cited by 401
Self-citation
Research works printed but not linked: 1
- Nasteska, 2012, Lowering GIP secretion has beneficial role in reducing obesity and insulin resistance without impairing glucose tolerance and osteogenesis, Diabetologia, 55, S80
Cited by
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
“Recent meta-analyses did not reveal systematic differences in GLP-1 or GIP secretion between healthy subjects and patients with T2D [10,12].”
BackgroundGLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394
“The most recent understanding of this deficit suggests that it relates to deterioration of the GLP-1 effect, with impaired capacity to secrete insulin, increasing insulin resistance, and hyperglycemia, perhaps leading to a decrease in GLP-1 receptor expression and resulting in GLP-1 resistance (7).”
BackgroundNauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
Yabe, D., Seino, Y., Fukushima, M., & Seino, S. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0602-9 · Cited by 328
Min, T., & Bain, S. C. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00981-0 · Cited by 285
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
“10 Finally, the effect of GLP-1RAs on weight may contribute to an increase in insulin sensitivity and better control of blood glucose.”
BackgroundAnti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Incretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
Enteroendocrine K and L cells in healthy and type 2 diabetic individuals
Jorsal, T., Rhee, N. A., Pedersen, J., Wahlgren, C. D., Mortensen, B., Jepsen, S. L., Jelsing, J., Dalbøge, L. S., Vilmann, P., Hassan, H., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4450-9 · Cited by 172
Self-citationReappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Equine hyperinsulinemia: investigation of the enteroinsular axis during insulin dysregulation
de Laat, M. A., McGree, J. M., & Sillence, M. N. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00362.2015 · Cited by 152
Heterozygous RFX6 protein truncating variants are associated with MODY with reduced penetrance
Patel, K., Kettunen, J. L. T., Laakso, M., Stančáková, A., Laver, T. W., Colclough, K., Johnson, M. B., Abramowicz, M., Groop, L., Miettinen, P. J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00895-9 · Cited by 149
Fisman, E. Z., & Tenenbaum, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01412-5 · Cited by 124
“A dual GLP‐1/GIP receptor agonist An ideal antidiabetic medication should present proven efficacy in lowering elevated glucose levels, promote weight loss, have low risk of hypoglycemia and offer cardiovascular benefits [18].”
BackgroundSparre‐Ulrich, A. H., Hansen, L. S., Svendsen, B., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13323 · Cited by 115
Self-citationMonteiro, M. P., & Batterham, R. L. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.053 · Cited by 105
Gut hormone polyagonists for the treatment of type 2 diabetes
Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 110
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 112
Self-citationGut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Michaliszyn, S. F., Mari, A., Lee, S., Bacha, F. F., Tfayli, H. M., Farchoukh, L. O., Ferrannini, E., & Arslanian, S. A. (2014) · Diabetes · doi:10.2337/db13-1951 · Cited by 105
Gabe, M. B. N., Sparre‐Ulrich, A. H., Pedersen, M. F., Gasbjerg, L. S., Inoue, A., Bräuner‐Osborne, H., Hartmann, B., & ROSENKILDE, M. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.040 · Cited by 96
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Junker, A. E., Gluud, L. L., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12462 · Cited by 89
Self-citationGlucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85
Self-citationChen, S., Okahara, F., Osaki, N., & Shimotoyodome, A. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00418.2014 · Cited by 88
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
Self-citationIncretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Michałowska, J., Miller-Kasprzak, E., & Bogdański, P. (2021) · Nutrients · doi:10.3390/nu13020351 · Cited by 68
Incretin physiology and pathophysiology from an A sian perspective
Cho, Y. M. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12305 · Cited by 80
Klementová, M., Thieme, L., Haluzík, M., Pavlovičová, R., Hill, M., Pelikánová, T., & Kahleová, H. (2019) · Nutrients · doi:10.3390/nu11010157 · Cited by 80
Thondam, S. K., Daousi, C., Wilding, J. P. H., Holst, J. J., Ameen, G. I., Yang, C., Whitmore, C., Mora, S., & Cuthbertson, D. J. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00347.2016 · Cited by 71
“However, in patients with type 2 diabetes mellitus (T2DM), despite preserved GIP secretion (11), the insulinotropic action of GIP is severely impaired (12, 16, 35).”
Self-citationThe Regulation of Peripheral Metabolism by Gut-Derived Hormones
Sun, E. W. L., Martin, A. M., Young, R. L., & Keating, D. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00754 · Cited by 71
Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M., & Stemmer, K. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12837 · Cited by 71
Yabe, D., Kuroe, A., Watanabe, K., Iwasaki, M., Hamasaki, A., Hamamoto, Y., Harada, N., Yamane, S., Lee, S., Murotani, K., et al. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.12.010 · Cited by 73
Self-citationBerglund, L. M., Lyssenko, V., Ladenvall, C., Kotova, O., Edsfeldt, A., Pilgaard, K. A., Alkayyali, S., Brøns, C., Forsblom, C. M., Jonsson, A. E., et al. (2015) · Diabetes · doi:10.2337/db15-0122 · Cited by 71
Zhang, R., Noronha, J. C., Khan, T. A., McGlynn, N. D., Back, S., Grant, S., Kendall, C. W. C., & Sievenpiper, J. L. (2023) · Nutrients · doi:10.3390/nu15041050 · Cited by 66
Farhadipour, M., & Depoortere, I. (2021) · Nutrients · doi:10.3390/nu13061839 · Cited by 75
DPP-4 inhibitors: focus on safety
Tella, S. H., & Rendell, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.977863 · Cited by 67
Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’
Skow, M., Bergmann, N. C., & Knop, F. K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12685 · Cited by 59
Self-citationMarrano, N., Biondi, G., Borrelli, A., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2021) · Biomolecules · doi:10.3390/biom11020286 · Cited by 56
“In addition, GIP has similar effects to GLP-1 in the hypothalamic regulation of food intake [38,216].”
BackgroundInfluentialGabe, M. B. N., van der Velden, W. J. C., Gadgaard, S., Smit, F. X., Hartmann, B., Bräuner‐Osborne, H., & ROSENKILDE, M. M. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13289 · Cited by 57
GIP analogues and the treatment of obesity-diabetes
Bailey, C. J. (2019) · Peptides · doi:10.1016/j.peptides.2019.170202 · Cited by 58
Milk in the prevention and management of type 2 diabetes: The potential role of milk proteins
Hidayat, K., Du, X., & Shi, B. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3187 · Cited by 54
Fridlyand, L. E., & Philipson, L. H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152869 · Cited by 55
Kahleová, H., Tura, A., Klementová, M., Thieme, L., Haluzík, M., Pavlovičová, R., Hill, M., & Pelikánová, T. (2019) · Nutrients · doi:10.3390/nu11030486 · Cited by 53
EJE PRIZE 2018: A gut feeling about glucagon
Knop, F. K. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0197 · Cited by 47
Self-citationPsaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 50
Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 48
Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist
Tall Bull, S., Nuffer, W., & Trujillo, J. M. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108332 · Cited by 43
Retinol-binding protein 2 (RBP2): biology and pathobiology
Blaner, W. S., Brun, P., Calderon, R. M., & Golczak, M. (2020) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2020.1768207 · Cited by 42
Yanagimachi, T., Fujita, Y., Takeda, Y., Honjo, J., Sakagami, H., Kitsunai, H., Takiyama, Y., Abiko, A., Makino, Y., Kieffer, T. J., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2016.12.009 · Cited by 39
Bae, J. H., Kim, L.-K., Min, S.-H., Ahn, C. H., & Cho, Y. M. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12831 · Cited by 42
Enteroendocrine Cells: Metabolic Relays between Microbes and Their Host
Plovier, H., & Cani, P. D. (2017) · Endocrine Development · doi:10.1159/000475736 · Cited by 36
GIP’s involvement in the pathophysiology of type 2 diabetes
Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170178 · Cited by 35
Self-citationCannarella, R., Curto, R., Condorelli, R. A., Lundy, S. D., Vignera, S. L., & Calogero, A. E. (2024) · Nature Communications · doi:10.1038/s41467-024-49765-1 · Cited by 35
Alpha- and beta-cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes
Calanna, S., Scicali, R., Pino, A. D., Knop, F. K., Piro, S., Rabuazzo, A. M., & Purrello, F. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0555-5 · Cited by 38
Self-citationRøder, M. E. (2017) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317735283 · Cited by 39
Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000894 · Cited by 34
Block, C. E. M. D., Dirinck, E. L., Verhaegen, A. A., & Gaal, L. F. V. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 37
Lee, S., Yang, K. J. Z., Brun, P., Silvaroli, J. A., Yuen, J. J., Shmarakov, I. O., Jiang, H., FERANIL, J. B., Li, X., Lackey, A. I., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay8937 · Cited by 35
Postprandial dysmetabolism: Too early or too late?
Pappas, C., Kandaraki, E., Tsirona, S., Kountouras, D., Kassi, G., & Diamanti‐Kandarakis, E. (2016) · HORMONES · doi:10.14310/horm.2002.1697 · Cited by 30
Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 28
Incretins in patients with rheumatoid arthritis
Segura, B. T., López‐Mejías, R., Domínguez‐Luis, M. J., de Vera-González, A. M., Delgado, A. G., Ubilla, B., Olmos, J. M., Hernández, J. L., González-Gay, M. Á., & Ferraz‐Amaro, I. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1431-9 · Cited by 29
Irwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides · doi:10.1016/j.peptides.2019.170203 · Cited by 27
Holst, J. J., Buse, J. B., Rodbard, H. W., Linjawi, S., Woo, V. C., Boesgaard, T. W., Kvist, K., & Gough, S. C. L. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815610124 · Cited by 27
Self-citationGóralska, J., Raźny, U., Polus, A., Dziewońska, A., Gruca, A., Zdzienicka, A., Dembinska-Kiec, A., Solnica, B., Micek, A., Kapusta, M., et al. (2020) · Nutrients · doi:10.3390/nu12020476 · Cited by 26
Christensen, M., Lund, A., Jørgensen, N. R., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa097 · Cited by 25
Self-citationKolic, J., Spigelman, A. F., Smith, A. M., Fox, J. E. M., & MacDonald, P. E. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.577510 · Cited by 26
Kobayashi, M., Satoh, H., Matsuo, T., Kusunoki, Y., Tokushima, M., Watada, H., Namba, M., & Kitamura, T. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0079 · Cited by 24
Recent advances in new-onset diabetes mellitus after kidney transplantation
Montada-Atin, T., & Prasad, G. V. R. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i5.541 · Cited by 24
Gut–adipose tissue crosstalk: A bridge to novel therapeutic targets in metabolic syndrome?
Silva, D., & Matafome, P. N. (2020) · Obesity Reviews · doi:10.1111/obr.13130 · Cited by 23
Tura, A., Bagger, J. I., Ferrannini, E., Holst, J. J., Knop, F. K., Vilsbøll, T., & Mari, A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.10.006 · Cited by 24
Self-citationLiu, C., Li, C., Cai, X., Zou, Y., Mo, J., chen, B., Cai, Y., Han, T., Huang, W., Qian, H., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104492 · Cited by 20
Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
Rosenberg, J., Jacob, J., Desai, P., Park, J., Donovan, L., & Kim, J. Y. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21053 · Cited by 20
Konończuk, K., Muszyńska-Rosłan, K. M., Konstantynowicz-Nowicka, K., Krawczuk‐Rybak, M., Chabowski, A., & Latoch, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073712 · Cited by 17
Nowak, M., Nowak, W., & Grzeszczak, W. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2022.0029 · Cited by 25
Koopman, A. D. M., Rutters, F., Rauh, S. P., Nijpels, G., Holst, J. J., Beulens, J. W. J., Alssema, M., & Dekker, J. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191114 · Cited by 17
Self-citationShekhawat, V. S., Bhansali, S., Dutta, P. R., Mukherjee, K. K., Vaiphei, K., Kochhar, R. K., Sinha, S. K., Sachdeva, N. K., Kurpad, A. V., Bhat, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41887-7 · Cited by 18
Monteiro, M. P. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.27537 · Cited by 16
Wang, G., Zhao, Z., Ren, B., Wu, Y., Zhang, X., Liu, J., Wang, L., Si, D., & Yang, M. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12627 · Cited by 16
Østoft, S. H., Bagger, J. I., Hansen, T. F., Hartmann, B., Pedersen, O. B., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0070 · Cited by 18
Self-citationIntestinal Enteroendocrine Cell Signaling: Retinol-binding Protein 2 and Retinoid Actions
Calderon, R. M., Smith, C. A., Miedzybrodzka, E. L., Silvaroli, J. A., Golczak, M., Gribble, F. M., Reimann, F. M., & Blaner, W. S. (2022) · Endocrinology · doi:10.1210/endocr/bqac064 · Cited by 15
O’Brien, P., Han, G., Ganpathy, P., Pitre, S., Zhang, Y., Ryan, J., Sim, P. Y., Harding, S., Gray, R., Preedy, V. R., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010137 · Cited by 15
Yao, Y., Li, X., Yang, X., Mou, H., & Wei, L. (2023) · Tissue and Cell · doi:10.1016/j.tice.2023.102108 · Cited by 14
Otsuka, Y., Yamaguchi, S., Furukawa, A., Kosuda, M., Nakazaki, M., & Ishihara, H. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej14-0148 · Cited by 14
Ma, J., & Vella, A. V. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00324 · Cited by 14
Incretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 13
Kheder, M. H., Sillence, M. N., Bryant, L. M., & de Laat, M. A. (2017) · Journal of Animal Science · doi:10.2527/jas.2017.1468 · Cited by 12
van Olst, N., Meiring, S., de Brauw, M., Bergman, J. J. G. H. M., Nieuwdorp, M., van der Peet, D. L., & Gerdes, V. E. A. (2020) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2020.03.003 · Cited by 13
Silvaroli, J. A., Plau, J., Adams, C. H., Banerjee, S., Widjaja‐Adhi, M. A. K., Blaner, W. S., & Golczak, M. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100054 · Cited by 12
Takahashi, H., Nakajima, A., Matsumoto, Y., Mori, H., Inoue, K., Yamanouchi, H., Tanaka, K., Tomiga, Y., Miyahara, M., Yada, T., et al. (2022) · Food & Nutrition Research · doi:10.29219/fnr.v66.7870 · Cited by 12
Stinson, S. E., Alzola, I. F. D. R., Hovendal, E. D. B., Lund, M. A. V., Fonvig, C. E., Holm, L. A., Jonsson, A. E., Frithioff‐Bøjsøe, C., Christiansen, M., Pedersen, O. B., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad728 · Cited by 13
Self-citationHNF1α defect influences post-prandial lipid regulation
St‐Jean, M., Boudreau, F., Carpentier, A. C., & Hivert, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177110 · Cited by 12
Eshghi, S. R. T., Fletcher, K., Myette‐Côté, É., Durrer, C. G., Gabr, R. Q., Little, J. P., Senior, P. A., Steinback, C. D., Davenport, M. H., Bell, G. J., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00154 · Cited by 13
The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection
Lindquist, P., Gasbjerg, L. S., Mokrosiński, J., Holst, J. J., Hauser, A. S., & ROSENKILDE, M. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.891586 · Cited by 11
Self-citationYabe, D., Kuwata, H., Iwasaki, M., & Seino, Y. (2015) · EMJ Diabetes · doi:10.33590/emjdiabet/10312637 · Cited by 11
Boer, G. A., Hunt, J. E., Gabe, M. B. N., Windeløv, J. A., Sparre‐Ulrich, A. H., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15894 · Cited by 13
Self-citation
Metadata
- Authors
- Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K.
- Affiliations
- University of Copenhagen (DK)
- St. Luke's-Roosevelt Hospital Center (US)
- Corresponding author
- Knop, Filip K.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-09-14
- Volume
- 36
- Issue
- 10
- Pages
- 3346-3352
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3781498
- OpenAlex
- W2079429014
- Cited by
- 158
- References
- 58
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 17 · 2023: 11 · 2022: 13 · 2021: 10 · 2020: 13 · 2019: 13 · 2018: 14 · 2017: 17 · 2016: 11 · 2015: 11 · 2014: 12 · 2013: 1
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Novo Nordisk Fonden (NNF12OC1015904)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK026687)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP secretion, type 2 diabetes, oral glucose tolerance test, test meal, incretin response, body mass index, age, HbA1c, insulin secretion
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glucose Tolerance Test, Humans, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.